ServiceNow Stock Tumbles as Slower Backlog Growth and Margin Erosion Force Valuation Reset

What happened

ServiceNow shares dropped sharply after the company's third-quarter report and guidance pointed to a notable slowdown in current remaining performance obligations (cRPO) growth and an earnings miss. While Q3 subscription revenue rose 21.0% and total RPO increased 22.0%, management guided Q4 cRPO growth to approximately 18.5%, well below the 20.5% just reported, signaling near-term backlog deceleration. The adjusted EPS miss and a step-down in subscription gross margin to 80.0% (versus an 81% full-year framework) compounded concerns that AI monetization and recent acquisitions are pressuring profitability even as AI ACV targets are raised. The stock's 31% decline through Oct. 29 erased recent gains and pushed the price below the deep-value report's $135 attractive entry level, yet the report's no-margin-of-safety assessment now hinges on whether the bear case (implied value $125) becomes more likely than the base case ($160). The report's WAIT rating and conviction of 3.5 remain appropriate as investors await evidence that AI-driven expansion can restore growth and margins without further multiple compression.

Implication

For investors, the 31% decline has moved the stock below the deep-value report's attractive entry of $135, which could offer an improved risk-reward if the business stabilizes. However, the weaker cRPO guidance and margin step-down increase the probability of the bear case scenario, where implied value is $125, necessitating caution. The core franchise remains strong with 98% renewal and expanding large-deal counts, but the premium multiple was predicated on sustained high growth and expanding margins, both now in question. A conservative approach would be to monitor the next two quarterly reports for cRPO growth holding above 18%, AI ACV exceeding $1.9 billion, and subscription gross margin recovering above 81% before committing capital. Until then, a WAIT stance is justified, with any new position sized modestly given the heightened uncertainty.

Thesis delta

The previous WAIT thesis was based on no margin of safety at $150, with attractive entry at $135 and trim above $175. The 31% decline now places the stock below the $135 threshold, potentially improving the entry point for patient investors, but the deterioration in cRPO growth and margins shifts some probability weight toward the bear case (implied value $125). Consequently, the thesis shifts from a straightforward WAIT to a cautious WAIT with a more favorable valuation but a higher bar for re-rating catalysts.